U.S. Army Medical Materiel Development Activity (USAMMDA) logo
U.S. Army Medical Materiel Development Activity

Traumatic Brain Injury Drug Treatment (TBI-DT)

Currently there are no FDA-approved drug therapies for Traumatic Brain Injury (TBI).

Description: An FDA-approved novel or repurposed generic drug treatment to be administered acutely (within 24 hours, in the field and fixed facilities) to limit brain damage and enhance recovery.

Requirement: A successful drug will minimize secondary injury, enable prolonged field care, reduce medical evacuations, and return service members to duty sooner, improving mission readiness.

Concurrent Phase II Adaptive Platform Trials Pipeline of Multiple TBI Drug Candidates


Seeking Medium to Large Pharma Interest & Partnerships

Last Modified Date: 06/27/2024